Compare KVHI & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVHI | ENTX |
|---|---|---|
| Founded | 1978 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.0M | 147.4M |
| IPO Year | 1996 | 2015 |
| Metric | KVHI | ENTX |
|---|---|---|
| Price | $6.57 | $3.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 74.7K | ★ 680.8K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | 0.04 | ★ 0.22 |
| Revenue | ★ $9,622,000.00 | $42,000.00 |
| Revenue This Year | $27.78 | N/A |
| Revenue Next Year | $36.03 | N/A |
| P/E Ratio | $163.25 | ★ $13.82 |
| Revenue Growth | ★ 3.82 | N/A |
| 52 Week Low | $5.09 | $0.91 |
| 52 Week High | $13.00 | $4.20 |
| Indicator | KVHI | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 58.80 |
| Support Level | $5.83 | $2.71 |
| Resistance Level | $6.94 | $3.08 |
| Average True Range (ATR) | 0.25 | 0.21 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 58.53 | 69.70 |
KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.